BioClinica to ‘Optimise’ Top-Ten pharma Co’s clinical trial operations.
The deal “officially makes BioClinica Optimiser the preferred choice of the world’s top pharmaceutical companies,” claims CEO, Mark Weinstein, who told Outsourcing-Pharma that six out of ten now use the product to optimise their clinical supply chains.
Describing Optimiser as a desktop application with a straightforward user- interface, which allows researchers to enter all of the relevant trial parameters, Weinstein branded Optimiser as the ‘world’s only’ clinical trial supply forecasting tool that simulates and optimises clinical supply chains.
According to Weinstein, the ‘top-ten’ global healthcare company, headquartered in the US, will use Optimiser in all of its studies to simulate and forecast clinical trial supply scenarios, beginning with its largest ones, which Weinstein says, could save “millions of dollars for a single study.”
“Optimizer fully supports forecasting and simulation for clinical supplies management for even the most complex trials,” said Weinstein, adding, “In this capacity, we expect Optimizer to change the way this company designs its trials, as well as gaining speed and flexibility in deployment and ongoing management of their trials.”
The tool allows clinical supply specialists to model an visualise their clinical supply chain for a study, by taking into account depot locations, shipping times, recruitment rates, dropout rates, buffer stock, restocking rules and subject randomisation rules, for example.
After results of the simulation have been evaluated the specialist is able to run an unlimited number of simulations to find the most efficient clinical trial design. “The simulation process helps study teams to identify and control situations, such as supply crisis, study delays, and unnecessary supply overages before they happen,” said Weinstein.
Compatible with Trident IWR/IVR
The deal with Optimiser closely follows BioClinica’s announcement of the launch of its new interactive voice response/interactive web response (IWR/IVR) product, Trident, which Weinstein said is complementary with Optimiser; Once a trial has been designed in Optimiser, he said, researchers can configure the IWR/IVR system to the same specifications.
Mentioning that many companies still use spread sheets to manage clinical trial forecasts, he went on to say that IVR systems are typically used to randomise patients entering a trial, however he believes “none of the other available technologies support integration with IVR/IWR systems like Optimiser.”
BioClinica say its client expects Optimiser to produce better information for designing studies with faster study starts, reduced patient participation drop-outs, less waste and overstocking and overall cost savings. “This is a win for both organisations,” said Weinstein.
